Search results for "CYP2D6"

showing 4 items of 24 documents

The recipient CYP2D6 allele 4-associated poor metabolizer status correlates with an early fibrosis development after liver transplantation

2011

Summary CYP2D6 is part of the cytochrome P450 system, which catalyzes biotransformation of endogenous substrates and xenobiotics. Approximately 10% of the Caucasian population has two null alleles, resulting in a poor metabolizer (PM) status. Mostly, allele four (CYP2D6*4) is responsible for the PM status, which is suspected to be associated with an accelerated fibrosis progression (FP). The aim of the present study was to analyze the role of the CYP2D6*4 genotype for FP after liver transplantation (LT). Genotypes were determined in liver biopsies (donor) and peripheral blood (recipient) by fluorescence resonance energy transfer. Data were correlated with clinical variables and risk factors…

Transplantationmedicine.medical_specialtyCYP2D6business.industrymedicine.medical_treatmentHazard ratioLiver transplantationmedicine.diseaseNull alleleGastroenterologyFibrosisInternal medicineImmunologyGenotypemedicineAllelebusinessAllele frequencyTransplant International
researchProduct

Severe Tremor After Cotrimoxazole-Induced Elevation of Venlafaxine Serum Concentrations in a Patient With Major Depressive Disorder

2013

: We describe a female patient who was an extensive metabolizer of cytochrome P450 isoenzyme (CYP) 2D6 and an intermediate metabolizer of CYP2C19 (genotype: CYP2C19 *1/*2). She exhibited high serum concentrations of venlafaxine and O-desmethylvenlafaxine and developed severe tremor after comedication with cotrimoxazole (sulfamethazole/trimethoprim). Venlafaxine is mainly metabolized by O- and N-demethylation. O-demethylation is catalyzed by the highly polymorphic CYP2D6 and N-demethylation by several enzymes, CYP2C19, CYP2C9, and CYP3A4. The observed overall pharmacokinetic effect was most probably the result of decreased N-demethylation of venlafaxine by (1) reduced expression of CYP2C19 d…

medicine.medical_specialtyCYP2D6Venlafaxine HydrochlorideVenlafaxineCYP2C19Severity of Illness IndexGastroenterologyAnti-Infective AgentsInternal medicineTremorTrimethoprim Sulfamethoxazole Drug CombinationHumansMedicineDrug InteractionsPharmacology (medical)PsychiatryCYP2C9PharmacologyDepressive Disorder MajorCYP3A4business.industryVenlafaxine HydrochlorideMiddle AgedCyclohexanolsmedicine.diseaseTrimethoprimCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6Major depressive disorderFemaleAryl Hydrocarbon HydroxylasesbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugTherapeutic Drug Monitoring
researchProduct

Regulation of cytochrome P450 IID by acute phase mediators in C3H/HeJ mice.

1992

Abstract Cytochrome P450 IID6 is a drug metabolizing enzyme and the major target antigen in LKM-1 antibody positive chronic active hepatitis. The histological hallmark of chronic active hepatitis is a lymphocytic infiltrate in the liver. It is unknown whether and how cytokines produced and secreted by these tissue infiltrating mononuclear cells regulate the cellular expression of cytochrome P450 IID6. To study the effect of interleukin 1, tumor necrosis factor and interleukin 6 on the hepatocellular RNA expression of cytochrome P450 IID, we injected each of the cytokines in C3H HeJ mice. We found a time-dependent suppression of the cytochrome in the liver. Six hours after the intraperitonea…

medicine.medical_treatmentIntraperitoneal injectionBiophysicsBiochemistryMixed Function OxygenasesMiceCytochrome P-450 Enzyme SystemmedicineEscherichia coliAnimalsHumansInterleukin 6Molecular BiologyHepatitisMice Inbred C3HbiologyInterleukin-6Tumor Necrosis Factor-alphaCytochrome P450InterleukinCell Biologymedicine.diseaseBlotting NorthernRecombinant ProteinsEndotoxinsCytokineCytochrome P-450 CYP2D6LiverImmunologybiology.proteinRNATumor necrosis factor alphaFemaleAntibodyInterleukin-1Biochemical and biophysical research communications
researchProduct

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics

2021

Over the last two decades, pharmacogenetics and pharmacokinetics have been increasingly used in clinical practice in Psychiatry due to the high variability regarding response and side effects of antipsychotic drugs. Specifically, long-acting injectable (LAI) antipsychotics have different pharmacokinetic profile than oral formulations due to their sustained release characteristics. In addition, most of these drugs are metabolized by CYP2D6, whose interindividual genetic variability results in different metabolizer status and, consequently, into different plasma concentrations of the drugs. In this context, there is consistent evidence which supports the use of therapeutic drug monitoring (TD…

medicine.medical_treatmentPopulationAripiprazolePharmaceutical ScienceContext (language use)ReviewPharmacology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinearipiprazolePharmacy and materia medicamedicineAntipsychoticsPaliperidoneeducationAntipsychoticPopulation pharmacokinetic modelspharmacogeneticseducation.field_of_studyRisperidonerisperidonemedicine.diagnostic_testbusiness.industryCYP2D6PaliperidoneRisperidoneLAIRS1-441antipsychoticsTherapeutic drug monitoringpopulation pharmacokinetic modelsPharmacogeneticsAripiprazolebusinesspaliperidone030217 neurology & neurosurgeryPharmacogeneticsmedicine.drug
researchProduct